Merck stock trades close to its 12-month high as Q2 2026 growth and Keytruda momentum support the outlook

Merck & Co., Inc. (US58933Y1055) stock is trading close to its recent 12-month high in mid-August 2026, supported by solid second-quarter revenue growth and continued strength in its oncology and animal health franchises as of August 17, 2026.

Recent market data show Merck shares quoted at $135.84 on the New York Stock Exchange, reflecting a modest daily gain of 0.23% and keeping the stock in a narrow range just below a 12-month peak level as of August 17, 2026.

For investors, the combination of mid-single-digit revenue growth, earnings that exceeded expectations, and a year-to-date share price rally above 20% underscores how central Merck's cancer therapy portfolio has become to the company’s medium-term growth story.

Q2 2026 earnings show steady revenue growth

An institutional holdings update on August 16, 2026 highlighted Merck’s most recent quarterly figures, reporting Q2 2026 revenue of $16.61 billion, an increase of 5.1% compared with the same quarter a year earlier and modestly ahead of analyst estimates of $16.37 billion for the period.

In the same update, Merck’s earnings per share for the quarter were stated at a loss of $0.13, beating the consensus expectation of a wider $0.26 loss and reflecting the impact of one-off items, while the underlying business maintained a net margin of 4.77% and a return on equity of 16.73% in Q2 2026.

Year-over-year, the quarterly revenue improvement of 5.1% in Q2 2026 contrasts with a prior-year quarter in which Merck reported $2.13 in earnings per share, illustrating how current-period EPS is shaped by specific charges rather than a deterioration in the company’s operating profitability.

Guidance for fiscal 2026 remains in place, with Merck forecasting full-year EPS in a range from 2.660 to 2.760, and sell-side analysts collectively expecting 2.77 EPS for the current fiscal year, signaling that consensus sits slightly above the midpoint of management’s own range.

Beyond the headline EPS numbers, Merck’s dividend policy continues to provide a cash-return component: a quarterly dividend of $0.85 per share is scheduled to be paid on October 7, 2026 to shareholders of record on September 15, 2026, equating to an annualized payout of $3.40 per share and a yield of 2.5% at recent price levels.

Share price, valuation, and 12-month high context

According to a same-day news overview for Merck’s stock, the shares closed at $135.78 at the end of trading on August 14, 2026, with extended-hours trading later that day showing a price of $135.50, while intraday quote data on August 17, 2026 put the stock marginally higher at $135.84.

With the stock opening near $135.78 ahead of the latest session and trading only slightly above that level in recent intraday action, Merck is described as hovering close to its 12-month high, which frames the current valuation against an analyst consensus target price of $135.50 for the shares.

This relationship between market price and consensus target implies that the stock is priced broadly in line with prevailing analyst expectations, leaving limited implied upside from the average target, even as the company continues to deliver mid-single-digit revenue growth and maintains a 2.5% dividend yield.

Year to date in 2026, Merck’s share price has risen 28.1%, significantly outpacing a 14.3% advance in its broader industry group, underscoring that investors have rewarded the company’s execution on key growth franchises and its ability to convert pipeline assets into commercial revenue.

For long-term holders, the share price trading at or just below its recent 12-month high levels, combined with a rising dividend stream, suggests a profile where total return is supported by both price appreciation and cash distributions, though the proximity to consensus valuation may limit short-term re-rating potential without additional growth catalysts.

Keytruda and animal health underpin growth

A sector-focused weekly overview of pharma and biotech published on August 17, 2026 highlighted Merck’s oncology and animal health activities, noting that recent press releases in the current period have included a Q2 2026 financial results announcement, regulatory progress on an RSV indication expansion for ENFLONSIA, and HIV pipeline data presentations at a major international conference.

Another analysis of Merck’s growth trajectory for the second half of 2026 emphasized the importance of Keytruda, Merck’s flagship PD-1 cancer immunotherapy, in sustaining revenue momentum and margin resilience as the company navigates life-cycle management and increasingly competitive oncology markets.

Within Merck’s Q2 2026 figures, a company communication cited total worldwide sales of $16.6 billion for the quarter on a reported basis, with the animal health division contributing $1.8 billion, representing 8% reported growth and 5% constant-currency growth, highlighting that the business’s diversification beyond human pharmaceuticals is adding incremental top-line expansion.

Comparing the animal health division’s 8% reported revenue increase with the company-wide 5.1% revenue growth underscores how Merck’s animal health portfolio is currently expanding faster than the consolidated business, providing a supportive backdrop for margins as the oncology franchise absorbs continued investment in clinical development and market access.

For Keytruda specifically, the focus in the second half of 2026 is on sustaining high-single- or double-digit sales growth and defending market share, with the drug’s performance central to Merck’s ability to meet or modestly exceed its stated full-year EPS guidance range of 2.660 to 2.760.

A representative product: Keytruda cancer immunotherapy

Keytruda is Merck’s best-known oncology product, a PD-1 immune checkpoint inhibitor approved across a broad spectrum of solid tumors, including lung cancer, melanoma, and several other indications, and it has become the cornerstone of the company’s cancer franchise and a key driver of overall revenue growth.

The therapy works by blocking the PD-1 pathway, which cancer cells often exploit to hide from the immune system, thereby restoring T-cell activity against tumors and enabling durable responses in many patients whose disease had previously been difficult to treat with conventional chemotherapy alone.

Over recent years, Keytruda has gained a series of label expansions through clinical trial success, and in the current period Merck is continuing to invest in new studies that aim to extend the drug’s reach into earlier-stage disease settings and additional tumor types, reinforcing its commercial potential in the second half of 2026 and beyond.

Merck stock and market positioning as of August 17, 2026

As of August 17, 2026, Merck & Co., Inc. stock is quoted at $135.84 on the New York Stock Exchange, with the price reflecting modest intraday gains and positioning the shares close to their 12-month high, while offering a 2.5% dividend yield based on the annualized $3.40 per share payout.

The company’s most recent Q2 2026 results, featuring $16.61 billion in revenue, 5.1% year-over-year growth, and EPS that beat consensus expectations by $0.13, combined with faster-growing animal health revenues and a year-to-date share price rally of 28.1% versus a 14.3% industry gain, frame Merck as a large-cap pharma name with a solid earnings base and a valuation already aligned with average analyst targets.

Fact box

Company: Merck & Co., Inc.

ISIN: US58933Y1055

Ticker: MRK

Exchange: New York Stock Exchange

Price (as of August 17, 2026): $135.84 USD

Market cap: not specified in the available sources

Sector / Industry: Pharmaceuticals / Biotechnology

Index membership: S&P 500